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Background. Thyroid status may influence tumorigenesis of gynecologic cancers, yet epidemiologic studies of this relationship are
limited and inconsistent. Methods. We evaluated the association of self-reported history of physician-diagnosed hypothyroidism
and hyperthyroidism with medical-record confirmed endometrial (EC; all invasive adenocarcinomas) and ovarian cancer (OC;
epithelial ovarian or peritoneal cancers) in Nurses’ Health Study (NHS) from 1976 to 2010 and NHSII from 1989 to 2011. Cox
proportional hazard models were used to estimate multivariable rate ratios (RRs) and 95% confidence intervals based on pooled
cohort data. Results. We confirmed 1314 incident cases of EC and 1150 cases of OC. Neither a history of hypothyroidism nor
hyperthyroidism was significantly associated with risk of EC or OC. However, having a history of hypothyroidism for 8+ years
(median) was nonsignificantly inversely associated with EC (RR= 0.81; 95% CI = 0.63–1.04; P-trend with history duration = 0.11)
and OC (RR= 0.87, 95% CI = 0.66–1.15; P-trend = 0.13). Having a history of hyperthyroidism for 6+ years (median) was non-
significantly positively associated with EC (RR= 1.69; 95% CI = 0.86–3.30; P-trend = 0.12) but not OC (RR= 1.12; 95% CI = 0.46–
2.72; P-trend = 0.95). Conclusions. A history of hypothyroidism or hyperthyroidism was not significantly associated with risk of EC
or OC.
1. Introduction
Endometrial cancer (EC) is the most common gynecologic
malignancy in the United States, and the fourth most com-
mon cancer overall in women [1]. Most cases are diagnosed
in postmenopausal women at an early stage and have an
excellent prognosis; however, those presentingwith advanced
or recurrent disease have limited treatment options and
survival of less than 3 years [2, 3].The number of deaths from
EC has doubled over the last 20 years, and the reason for this
is not well understood [4].Well established risk factors for EC
are hormonally linked and include a greater lifetime exposure
to estrogen, obesity, and diabetes and display a progression
from atypical hyperplasia to cancer [5, 6]. Similarly, ovarian
cancer (OC) risk is estrogen-linked but very little is known
about the etiology or its precursors and it remains the most
lethal gynecologic cancer [7]. The hypothalamic-pituitary
axis (HPA) regulates the female reproductive tract not only
through the regulation of estrogen and other sex hormones
but also through interactions with related pathways including
thyroid hormones [8].
Thyroid hormones (T3 and T4) are important regulators
of differentiation, growth, and metabolism of virtually all
tissues including the ovaries and endometrium [8–11]. Thy-
roid disorders can present as hyperthyroidism (excessive T3
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and T4 production) or more commonly as hypothyroidism
(decreasedT3 andT4production)with a higher prevalence of
both disorders affectingwomen [12].Menstrual irregularities,
anovulation, and infertility are common symptoms of both
types of thyroid disorders and result from both direct and
indirect effects on the endometrium and ovaries [13, 14].
Direct binding of thyroid hormones to receptors on ovarian
surface epithelium, ovarian follicles, and the endometrial lin-
ing influences proliferation and regulation of menstruation
[15, 16]. Indirectly, alterations in thyroid hormone levels cause
changes in serum levels of sex hormone binding globulin
(SHBG), sex hormones (estrogen and testosterone), and their
metabolism and clearance from the body [17, 18]. These
alterations in hormone levels may then impact the risk of EC
or OC.
Due to the ubiquitous role of thyroid hormones, it has
been hypothesized that they may influence cancer develop-
ment and growth in various tissues [19–21]. This association
has recently been clarified after a membrane cell surface
receptor for thyroid hormones was characterized on rapidly
dividing cells (e.g., endometrium) in contrast to the usual
intracellular transport and nuclear binding in other tissues
[22, 23]. Several in vitro and in vivo studies have implicated
thyroid hormones in tumorigenesis and cell proliferation in
glioma, gastric, and breast cancer cell lines [21]. Blocking thy-
roid hormone receptors or decreasing T3 and T4 production
to induce hypothyroidism has been shown to reduce tumor
growth in breast, prostate and hepatocarcinomamousemod-
els [20–23].
Observational studies in lung, colon, prostate, and breast
cancer patients have reported conflicting results regarding
the relationship of thyroid hormones with increased cancer
risk [24–27]. A recent large population study in Norway
reported an association between hyperthyroidism and risk of
lung and prostate cancer, but gynecologic cancers were not
assessed [28]. Only one record-linkage analysis has examined
the relationships of uterine and ovarian cancer risk with
pre-existing chronic conditions and reported that thyroid
diseases (types of disease were not specified) were associated
with a significant risk of EC (RR 1.52) [29].
Given that thyroid disorders and alterations in thyroid
hormone expression influence ovulation, endometrial physi-
ology, and estrogen levels, further exploration into the poss-
ible association with gynecologic cancer risk is warranted.
Thus, we evaluated the association between self-reported
history of physician-diagnosed hypothyroidism and hyper-
thyroidism in Nurses’ Health Study (NHS) from 1976 to 2010
and NHSII from 1989 to 2011 in relation to risk of medical-
record confirmed ECs and OCs.
2. Methods
2.1. Study Population. The NHS started in 1976 with 121,700
US female registered nurses aged 30–55 years, and the NHSII
started in 1989with 116,430U.S. female registered nurses aged
25–42 years. Participants completed baseline questionnaires
in both cohorts and since have been followed with biennial
questionnaires, providing information on various lifestyle
factors and diagnosed diseases. Participant followup is high
in both cohorts; >90% of the total possible person-years
through June 2010 in the NHS and through June 2011 in the
NHSII were obtained. This investigation was approved by
the Institutional Review Board of the Brigham and Women’s
Hospital and/or the Harvard School of Public Health.
2.2. Ascertainment and Validation of
Hypothyroidism and Hyperthyroidism
2.2.1. Ascertainment of Hypothyroidism Diagnosis
NHS. On the 2002 questionnaire, participants were asked
about ever having had a diagnosis of physician-diagnosed
hypothyroidism and the date of diagnosis. In addition, par-
ticipants had the opportunity to report physician-diagnosed
hypothyroidism on each biennial questionnaire from 1978 to
2008, where they were asked to write-in physician-diagnosed
diseases; write-in diseases assigned with ICD codes of “244”
were considered self-reports of hypothyroidism.
NHSII.On the baseline 1989 questionnaire, participants were
asked about a “history of thyroid disease” diagnoses (with-
out specifying hyperthyroidism or hypothyroidism), date of
diagnosis, and current use of thyroid hormone replacement
therapy. Those who reported having a “thyroid disease”
diagnosis aswell as reported currently using thyroid hormone
replacement therapy were considered as having a history of
hypothyroidism, as in our data from later cycles; among those
who report thyroid hormone replacement therapy at a given
cycle, a report of hypothyroidism was more than 10 times
more common than a report of hyperthyroidism in the same
cycle. In 1993, participants were asked if they had developed
hypothyroidism and the date of diagnosis, and starting
from 1995 to 2009, they were asked if they had developed
hypothyroidism in the preceding 2 years. As in theNHS, from
1989 to 2009, participants also had the opportunity to write-
in hypothyroidism; write-in reports assigned with ICD codes
of “244” were considered as hypothyroidism reports.
2.2.2. Ascertainment of Hyperthyroidism Diagnosis
NHS. On the 2002 questionnaire, participants were asked
about ever having had a diagnosis of physician-diagnosed
hyperthyroidism (“Graves’ disease/Hyperthyroidism”) and
the date of diagnosis, and starting in 2004–2008, they were
asked about hyperthyroidism diagnoses in the preceding 2
years. In addition, participants had the opportunity to report
physician-diagnosed hyperthyroidism on each biennial ques-
tionnaire from 1978 to 2008, where they were asked to write-
in physician-diagnosed diseases; write-in diseases assigned
with ICD codes of “242” were considered self-reports of
hyperthyroidism.
NHSII. In 1993, participants were asked if they had developed
Graves’ disease before or after baseline, and starting in 1995,
they were asked if they had developed “Graves’ disease”
or “Graves’ hyperthyroidism” in the preceding 2 years. As
in the NHS, from 1989 to 2009, participants also had the
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opportunity to write-in hyperthyroidism diagnoses; write-in
reports assigned with ICD codes of “242” were considered as
hyperthyroidism reports.
2.2.3. Validation of Hypothyroidism and Hyperthyroidism
Hypothyroidism. We conducted a pilot study among NHSII
participants who had self-reported hypothyroidism on bien-
nial questionnaires. First, we sent participants a supple-
mentary questionnaire asking about their diagnosis date,
medication use, prior history of hyperthyroidism, postpar-
tum thyroiditis, thyroid treatment (radioactive iodine treat-
ment, thyroid surgery, etc.), and family history of hypothy-
roidism. In addition, we asked participants for permission
to retrieve their medical records from diagnosing health
care providers. We received relevant medical records for 68
participants; of these, a clinical diagnosis of hypothyroidism
and current levothyroxine/desiccated thyroid prescription
was documented in 100%, and in 56 (82%), laboratory results
demonstrated abnormal and persistently elevated TSH values
(>4.5mIU/L) or presence of Hashimoto’s thyroiditis based on
clinical factors (family history) in addition to biochemical
(TPO Ab > 20 IU/mL without TSH > 4.5mIU/L) and/or
radiologic markers (thyroid ultrasound with diffuse hetero-
geneous pattern). Thus, we can successfully identify cases of
primary hypothyroidism in these populations of health care
professionals.
Hyperthyroidism. A validation study was performed among
72 women in NHSII who reported having Graves’ hyper-
thyroidism on the biennial questionnaire to assess the reli-
ability of self-reports [30]. Supplemental questionnaires and
requests for permission to obtain medical records from
the treating physician were sent to these participants. The
supplemental questionnaire asked about whether they had
been diagnosed as having Graves’ disease or Graves’ hyper-
thyroidism and the year of diagnosis; symptoms and signs
of hyperthyroidism; whether they had goiter or eye changes;
tests done to confirm the diagnosis (thyroid function tests,
thyroid scan and uptake, and ophthalmologic examination);
antithyroid drug, radioiodine, or surgical treatment; and
diagnosis of other thyroid disorders (hyperfunctioning nod-
ule, multinodular goiter, hypothyroidism, or thyroid cancer).
The diagnosing physicians of record were asked to send
copies of medical information confirming the diagnosis, if
participants granted permission. Criteria for the diagnosis
of Graves’ hyperthyroidism included test results indicative
of hyperthyroidism, initiation of treatment for hyperthy-
roidism, and absence of other thyroid disorders. Based
on review of the supplemental questionnaire and medical
records, the diagnosis of Graves’ hyperthyroidism was cor-
roborated in 61 (85%) of the 72 women, demonstrating the
high validity of the self-reports of Graves’ hyperthyroidism
in this population.
2.3. Identification of Cancer Cases. In both NHS and NHSII,
we collected information on new EC and OC diagnoses
on each questionnaire at baseline and on all biennial
questionnaires. In addition, deaths due to EC or OC were
identified through information from family members, the
U.S. National Death Index, or the U.S. Postal Service. For
all reported cases and deaths, we obtained medical records
related to the diagnosis. For both outcomes, a gynecologic
pathologist masked to thyroid disease status reviewed the
medical records to confirm the diagnosis, stage, histologic
type/subtype, and degree of invasiveness. For EC, we iden-
tified 1314 cases of invasive adenocarcinomas defined by
the International Federation of Gynecology and Obstetrics
(FIGO) as stages IB to IVB diagnosed between June 1976 and
June 2010 in NHS and June 1989 and June 2011 in NHSII.
(In alternate analyses of 1786 cases of stage 1A to IVB, results
were similar (data not shown); thus, these analyses focused on
the invasive cancers of stages IB to IVB, which are of greater
clinical and public health significance). For OC, we included
all epithelial OC and primary peritoneal cases confirmed by
pathology report review (𝑛 = 1150) diagnosed during the
same period.
2.4. Statistical Analysis. Analyses were conducted separately
for each outcome using the combined NHS and NHSII
datasets. At baseline, we excluded women with existing
cancer other than nonmelanoma skin cancer, women with
missing data on the dates of diagnoses of hypothyroidism
or hyperthyroidism and women reporting other thyroid
disorders. Participants accrued person-time from the return
date of the baseline questionnaire until the date of EC/OC
diagnosis, diagnosis of any other cancer (excluding non-
melanoma skin cancer), diagnosis of other thyroid disorders,
death, or end of followup.
For EC, at baseline and during followup, we excluded
women who reported a hysterectomy from contributing
person-time. The total numbers of women who ever con-
tributed person-time in the EC analyses were 95,135 in
the NHS and 105,027 in the NHSII. For OC, at baseline
and during followup, we censored women with bilateral
oophorectomy and menopause due to pelvic irradiation. The
total numbers of women who ever contributed person-time
in the OC analyses were 108,609 in the NHS and 108,733 in
the NHSII.
We used time-varying Cox proportional hazards regres-
sion models, stratified by age, time period at risk (from
one questionnaire return to the return of the next ques-
tionnaire/end of followup), and cohort (NHS or NHSII)
to model the age-adjusted and multivariable incidence rate
ratios (RR) and 95% confidence intervals (CI) in relation to
each outcome for both history of hypothyroidism and history
of hyperthyroidism in the NHS and NHSII combined data.
In addition, we evaluated EC and OC risk with the duration
of having a history of each thyroid disease (<6 or ≥6 years,
median time since diagnosis of hyperthyroidism and <8 or
≥8 years, median time since diagnosis of hypothyroidism),
and we conducted tests for trend for duration of history
of thyroid disease. In multivariable models, we adjusted
for major lifestyle and reproductive factors for EC and OC
determined a priori from the previous literature; the specific
covariates and their specifications are provided in the foot-
notes to the main results tables.The covariates adjusted for in
multivariable models represent cumulative histories as of the
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questionnaire immediately before the 2-year risk cycle (e.g.,
updated bodymass index info was available every 2 years and
at each biennial questionnaire cycle, we calculated the average
of all of the available body mass index measurements and
medical history (e.g., diabetes), and duration variables (pack-
years of smoking) were updated at each cycle).
We performed several secondary analyses. To evaluate
whether surveillance bias might explain potential associ-
ations, as the diagnosis of hypothyroidism and hyperthy-
roidism may be correlated with better access to health
care/health consciousness that leads to greater frequency
of ovarian/EC diagnoses, we conducted secondary analyses
where we adjusted for high cholesterol (often an indication
for thyroid testing) and having had a routine physical exam.
Also, because hypothyroidism can be transient, to capture
chronic conditions, we conducted alternative analyses where
hypothyroidism was considered to be present only if it was
reported at least twice during the follow-up period (and the
date of diagnosis was the earliest reported date); because
hyperthyroidism was rarely reported, we did not conduct
similar analyses for hyperthyroidism as this had poor power.
For EC, because body mass index is a strong risk factor,
and body mass index also is strongly associated with thyroid
status, we conducted analyses stratified by body mass index
(<25 or ≥25 kg/m2, which is the median body mass index).
For OC, we conducted analyses where we restricted analyses
to OC with serous invasive/poorly differentiated histology.
3. Results
A history of hyperthyroidism was rare, with 0.6% of the total
person-time of followup, while a history of hypothyroidism
comprised 6–8% of the total person-time of followup in the
cohorts (Table 1). In general, compared to those without any
thyroid dysfunction, those with a history of hypothyroidism
had higher body mass index, greater frequency of hyperten-
sion and diabetes, current estrogen use, tubal ligation, history
of infertility, and family history of breast, ovarian, or uterine
cancer. Compared to those without thyroid dysfunction,
those with a history of hyperthyroidism had lower or similar
body mass index, greater frequency of long-term smoking,
hypertension (and diabetes inNHS), history of infertility, and
family history of uterine cancer.
3.1. Endometrial Cancer. During 34 years of followup in the
NHS, we documented 1131 cases of incident EC inwomen and
during 22 years of followup in the NHSII, we documented
183 cases (Table 2). Age-adjusted and multivariable adjusted
analyses were similar. Neither a history of hypothyroidism
nor hyperthyroidism was significantly associated with risk
of EC: the multivariable RR for a history of hypothyroidism
was 0.91 (95% CI = 0.75, 1.10), while the RR for a history
of hyperthyroidism was 1.43 (95% CI = 0.85, 2.39). The data
suggested that a history of hypothyroidism, especially having
such a history for 8+ years or greater (the median time),
was nonsignificantly inversely associated with EC risk (RR of
8+ years with a history of hypothyroidism = 0.81; 95% CI =
0.63–1.04; 𝑃-trend with duration = 0.11). In contrast, having
a history of hyperthyroidism for 6+ years (median time) was
associated with a nonsignificantly increased risk (RR = 1.69;
95% CI = 0.86–3.30; 𝑃-trend with duration = 0.12).
In secondary analyses additionally controlling for report
of routine physical exam and high cholesterol (an indication
for thyroid testing), results were generally similar to the
main results (Table 2). When we considered a history of
hypothyroidism to be present only when it was reported at
least twice during followup, we observed somewhat stronger
inverse associations with a history of hypothyroidism (RR =
0.79, 95% CI = 0.62–1.00) and having had a history of
hypothyroidism for 8+ years (RR = 0.78, 95% CI = 0.59–
1.03; 𝑃-trend with time since diagnosis = 0.04). In analyses
stratified by body mass index (<25 or ≥25 kg/m2), inverse
associations with a history of hypothyroidism were mainly
observed in those with higher than median body mass index:
the RR for having a history of hypothyroidism for 8+ years
was 0.77 (95% CI = 0.57–1.04; 𝑃-trend = 0.09) for those with
body mass index ≥ 25 kg/m2, while the corresponding RR for
those below the median body mass index of 25 kg/m2 was
0.96 (95% CI = 0.59–1.57; 𝑃-trend = 0.95); however, the p for
interaction between body mass index and hypothyroidism in
relation to EC was not significant (𝑝 for interaction was 0.15
for hypothyroidism status and 0.23 for duration of having a
history of hypothyroidism).
3.2. OvarianCancer. During 34 years of followup in theNHS,
we documented 908 cases of incident OC in women and
during 22 years of followup in theNHSII, we documented 242
cases (Table 3). We observed that neither a history of hypoth-
yroidism (RR = 0.84, 95% CI = 0.68–1.04) nor hyperthy-
roidism (RR = 0.67, 95% CI = 0.30–1.49) was significantly
associated with OC. Having a history of hypothyroidism for
8+ years (median) was non-significantly inversely associated
OC (RR = 0.87, 95% CI = 0.66–1.15; 𝑃-trend = 0.13). Having
a history of hyperthyroidism for 6+ years (median) was not
associated with OC (RR = 1.12; 95% CI = 0.46–2.72; 𝑃-trend
= 0.95).
In secondary analyses where we additionally controlled
for report of routine physical exam and high cholesterol,
results were generally similar to the main results (Table 3).
When we considered a history of hypothyroidism to be
present only when it was reported at least twice during fol-
lowup, we observed significant inverse associations between
overall history of hypothyroidism (RR = 0.76, 95% CI =
0.58–0.99) and having had a history of hypothyroidism for
8+ years (RR = 0.81, 95% CI = 0.60–1.10; 𝑃-trend with
time since diagnosis = 0.06). Analyses of OC with serous
invasive histology or poorly differentiated histology showed
similar weak nonsignificant associations with a history of
hypothyroidism or hyperthyroidism as the main results (RR
= 0.84, 95%CI = 0.64–1.11 for hypothyroidism and RR = 0.56,
95% CI = 0.18–1.76 for hyperthyroidism).
4. Discussion
In the largest cohort study to date to specifically evaluate
the association between thyroid disorders and gynecologic
cancer risk, we observed no significant associations of self-
reported history of hypothyroidism and hyperthyroidism
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with either EC or OC risk. However, there was a sugges-
tive weak inverse association of having a longer history of
hypothyroidism with both gynecologic cancer outcomes and
a modest positive association of having a longer history of
hyperthyroidism with EC.
Previous epidemiologic studies evaluating the impact of
thyroid disorders on cancer risk have not been conclusive [20,
31–33]. Breast cancer is a hormone-dependent cancer and is
one of the firstmalignancies to be associatedwith thyroid dis-
ease. Case-control studies in breast cancer patients observed
a significantly reduced risk of breast cancer in women with
untreated hypothyroidism [34]. Conversely, postmenopausal
women with elevated thyroid hormone levels and subclinical
hyperthyroidism had a higher rate of breast cancer than
matched controls [35]. A recent meta-analysis of 28 studies
evaluating any type of benign thyroid disorder or nodule and
breast cancer risk reported no significant associations overall,
but heterogeneity across studies limited the conclusions
[36]. For total cancer risk assessment, Hercbergs et al. [27]
conducted a large prospective study of almost 30,000 people
and followed their thyrotropin levels (TSH) for over 9 years.
Low levels, suggestive of subclinical hyperthyroidism, were
associated with an increased risk of lung and prostate cancer
but not breast or colon cancer. Despite our large cohort,
we still had relatively small numbers of cancer cases with
self-reported thyroid disease overall and did not observe a
significant association for either type of thyroid disorder and
EC in contrast to the findings of Brinton et al. [29].
We observed a nonsignificant trend towards increased
risk of ECwith longer duration of history of hyperthyroidism
(>6 years). The mechanism by which chronic hyperthy-
roidism might increase the risk of EC is not fully understood
[37–40]. The endometrium is a complex system influenced
by a delicate balance of steroid hormones receptors, growth
factors, and cytokines. Women with hyperthyroidism have
estrogen levels 2- to 3-fold higher compared to euthyroid
women due to SHBG changes and decreased clearance of
estradiol [17, 18]. Over time, chronic hyperthyroidism may
indirectly increase serum estradiol levels and increase EC
risk. Preclinical data has identified a class of cell surface
receptors in the endometrium that bind thyroid hormone
directly and expression is correlated with infertility and
implantation defects [41–43]. Disordered growth of the
endometrium is a precursor for endometrial hyperplasia
and subsequent progression to carcinoma. Women with
prolonged exposure to higher levels of thyroxine, as seen with
hyperthyroidism, may be at risk for developing endometrial
hyperplasia and EC by direct binding and proliferation, but
further research is needed to investigate this association. In
addition, the medical treatment of hyperthyroidism and the
impact of thyroid blocking medications on the endometrium
have not been well characterized.
Conversely, we found a nonsignificant association
between hypothyroidism and decreased EC risk. Previous
studies have confirmed that hypothyroidism results in
decreased estradiol levels and altered regulation from the
HPA. The resulting anovulation and thin endometrial lining
may potentially be protective over time and balance the
obesity often associated with hypothyroidism [16]. The
validation used in our cohort for self-reporting their diag-
noses was excellent; however, confirming length of treatment
and proper medication usage and, if possible, blood testing
would be needed in future work.
We did not observe an association between history of
hyperthyroidism or history of hypothyroidism and the risk of
OC. Research on OC has been limited by the low incidence
and inability to easily access the ovaries to understand the
precursors to malignant transformation. The incessant ovu-
lation theory links ovulation to epithelial damage, inflamma-
tion, and repair that can lead to OC and is a hormone depen-
dent process.The ovaries express estrogen, progesterone, and
thyroid receptors; however, their complex interactions are not
fully understood and the impact on cancer development, if
any, remains unclear [7, 44]. Our findings do not support a
hormonal etiology as it relates to thyroid disease, although
a modest association cannot be ruled out. Only two other
reports have looked into this association with conflicting
results. Brinton et al. [29] reviewed over 2500 OC cases
from a Danish tumor registry and reported no association
with thyroid disease; however, they were based on hospital
diagnoses and only included 39 cases of thyroid disease. The
other report was a population-based case-control study that
suggested a significant relationship between hyperthyroidism
andOC [45]. A follow-up study identified the ovarian surface
epithelium as a target for thyroid hormone in vitro resulting
in increased expression of estrogen [46]. Pooled or meta-
analysis studies are needed to increase power to further
examine these associations.
The strengths of this study include the fact that thyroid
disease was ascertained before disease diagnoses, the large
sample size of nearly 200,000 women, and the repeated and
updated measures. A major limitation of our study was that
we did not have measurements of thyroid hormone levels in
our population and evaluated the associations with condi-
tions related to having extreme levels of thyroid hormones,
and thus we were not able to evaluate dose-response relations
of thyroid hormones to risk of EC/OC.However, associations,
if present, are likely to be detectable by evaluating chronic
conditions that arise due to either abnormally very high
or very low thyroid levels, and evaluations of the thyroid
disorders was more feasible. Another major limitation was
that we used self-reports of a history of hypothyroidism and
a history of hyperthyroidism; while the validation studies
of self-reports showed that a high percentage of all the
self-reports were likely to be accurate in this population
of nurses, there was likely underascertainment of thyroid
disease in the population compared to if we had conducted
in-person exams or measured thyroid hormone levels for
all participants. This underascertainment would have likely
caused some bias towards the null, which might explain
some of the weak associations observed. We also lacked
detailed information on the types, duration, and effectiveness
of any treatments that participants might have received;
therefore, if there were possible associations with a history of
hypo- or hyperthyroidism, it is not clear whether it was the
disease per se or treatments for these conditions that may be
underlying the associations. Also, because hyperthyroidism
was relatively rare in the population, there were few cases of
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cancer with a history of hyperthyroidism, and so we lacked
power to detect modest associations. We also lacked power
to conduct analyses by EC/OC histologic subtype of genetic
predisposition. Because some thyroid dysfunction may be
subclinical or mild in presentation, any associations with
thyroid dysfunction may arise solely due to better medi-
cal surveillance. However, when we additionally adjusted
for participant’s history of receiving physical exams or a
diagnosis of high cholesterol (which often prompts thyroid
testing), results were similar, indicating minimal bias due
to better surveillance of health outcomes in those with
thyroid dysfunction. Finally, because this study was done in
populations of mostly well educated, nonobese Caucasian
women, there may be issues of generalizability ability to the
general population; however, it is not likely that the biological
mechanisms may differ by race, ethnicity, or socioeconomic
status.
In summary, a self-reported history of hypothyroidism
or hyperthyroidism was not significantly associated with risk
of EC or OC. However, these data were consistent with
possible weak inverse associations with a history of hypothy-
roidism for both outcomes and adverse associations with a
longer history of hyperthyroidism and EC risk. As research
continues to evolve into the complex interactions between
thyroid hormones, steroid receptors, and sex hormones on
the female reproductive tract, we may identify new pathways
associated with gynecologic cancer risk. Further studies
are needed to clarify the origins of a possible relationship
between abnormal thyroid hormone expression and EC risk
and the potential for identifying new prevention or treatment
strategies.
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